2.01
前日終値:
$1.98
開ける:
$1.97
24時間の取引高:
56,081
Relative Volume:
0.30
時価総額:
$7.68M
収益:
$895.50K
当期純損益:
$-26.30M
株価収益率:
-1.2256
EPS:
-1.64
ネットキャッシュフロー:
$-23.84M
1週間 パフォーマンス:
-4.29%
1か月 パフォーマンス:
-43.54%
6か月 パフォーマンス:
-77.16%
1年 パフォーマンス:
-93.04%
Mainz Biomed N V Stock (MYNZ) Company Profile
MYNZ を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
MYNZ
Mainz Biomed N V
|
2.01 | 8.01M | 895.50K | -26.30M | -23.84M | -1.64 |
![]()
TMO
Thermo Fisher Scientific Inc
|
402.82 | 148.60B | 42.90B | 6.52B | 6.72B | 17.05 |
![]()
DHR
Danaher Corp
|
189.90 | 132.07B | 23.82B | 3.77B | 4.90B | 5.15 |
![]()
IDXX
Idexx Laboratories Inc
|
513.36 | 40.34B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
A
Agilent Technologies Inc
|
111.92 | 30.82B | 6.63B | 1.17B | 1.19B | 4.05 |
![]()
IQV
Iqvia Holdings Inc
|
140.33 | 23.70B | 15.50B | 1.33B | 2.16B | 7.34 |
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-02-14 | 開始されました | Maxim Group | Buy |
2024-11-25 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2023-11-21 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2022-06-21 | 開始されました | H.C. Wainwright | Buy |
Mainz Biomed N V (MYNZ) 最新ニュース
Maxim Group to Act as Sole Placement Agent for MYNZ Offering | M - GuruFocus
Mainz Biomed N.V. Secures $4 Million Through Securities Offering - TipRanks
Mainz Biomed (NASDAQ:MYNZ) Trading Up 5.4% – What’s Next? - Defense World
Mainz Biomed (MYNZ) Prices $4M Follow-On Offering - GuruFocus
Maxim Group to Act as Sole Placement Agent for MYNZ Offering | MYNZ Stock News - GuruFocus
Mainz Biomed Announces Pricing of $4 Million Follow-On Offering and Warrant Amendments - Nasdaq
Cancer Detection Company Mainz Biomed Raises Fresh $4M: Key Details of Share and Warrant Offering - Stock Titan
Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants - GlobeNewswire
Mainz Biomed stock plunges to 52-week low of $2.18 amid market challenges - Investing.com Nigeria
Trend Tracker for (MYNZ) - news.stocktradersdaily.com
Mainz Biomed to update on CRC screening study by end of summer - Investing.com South Africa
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study - GlobeNewswire
Mainz Biomed Plans Interim Readout For EAArly DETECT 2 CRC Study - Nasdaq
Revolutionary Cancer Prevention: Mainz Biomed Combines AI and mRNA in 2,000-Patient Colorectal Screening Trial - Stock Titan
Mainz Biomed (MYNZ) to Deliver Interim Results for Cancer Screening Study by 2025 | MYNZ Stock News - GuruFocus
MYNZ Stock Update: Maxim Group's Role as Manager | MYNZ Stock News - GuruFocus
Mainz Biomed to hold annual meeting on June 2 - Investing.com Australia
Mainz Biomed to hold annual meeting on June 2 By Investing.com - Investing.com Canada
Mainz Biomed Prepares for June 2025 Annual General Meeting - TipRanks
Stocks of Mainz Biomed N.V (MYNZ) are poised to climb above their peers - Sete News
Investing in Mainz Biomed N.V (MYNZ): What You Must Know - knoxdaily.com
Mainz Biomed Enters into Technology Partnership with EDX Medical Group - MSN
MYNZ Partners with EDX Medical to Enhance Diagnostic Offerings i - GuruFocus
Strategic Partnership: Mainz Biomed and EDX Medical Join Forces to Transform Early Cancer Detection in UK Market - Stock Titan
Mainz Biomed (MYNZ) Sees Revenue Surge Amid Strong Demand for Co - GuruFocus
Mainz Biomed N.V (NASDAQ: MYNZ) Is Expected To Soar To Higher Prices In The Months To Come. - Marketing Sentinel
Mainz Biomed advances in FDA approval for CRC test By Investing.com - Investing.com South Africa
Mainz Biomed advances in FDA approval for CRC test - Investing.com Australia
The Mainz Biomed N.V (MYNZ) Stock Is Headed for a Correction - uspostnews.com
MYNZ: Mainz Biomed Advances Cancer Detection with New Feasibilit - GuruFocus
Mainz Biomed N.V. Reports Q1 2025 Accomplishments and FDA Premarket Approval Progress - Nasdaq
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval - GlobeNewswire
Mainz Biomed's Game-Changing Cancer Test Shows 98% Accuracy as Company Expands European Presence - Stock Titan
Mainz Biomed (NASDAQ:MYNZ) Short Interest Down 48.7% in April - Defense World
Mainz Biomed (MYNZ) Sees Revenue Surge Amid Strong Demand for ColoAlert - GuruFocus
Long Term Trading Analysis for (MYNZ) - news.stocktradersdaily.com
Mainz Biomed (NASDAQ:MYNZ) Trading Up 3.9% – What’s Next? - Defense World
Colorectal to Pancreatic: Mainz Biomed Expands Reach in Early Cancer Detection - Markets Herald
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update - ADVFN
(MYNZ) Investment Report - news.stocktradersdaily.com
Mainz BioMed's Trial To Bring Critical Early Cancer Detection One Step Closer - Benzinga
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Mainz Biomed Reports 2024 Financial Success and Strategic Advances - TipRanks
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire Inc.
Virtu Financial LLC Takes $79,000 Position in Mainz Biomed (NASDAQ:MYNZ) - Defense World
Mainz Biomed N V (MYNZ) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):